Home From Dr. Google to CE-marked medical devices: need for ethical and legal safeguards
Article Open Access

From Dr. Google to CE-marked medical devices: need for ethical and legal safeguards

  • Mariagrazia Marisei , Enrico Sicignano ORCID logo EMAIL logo , Biagio Barone , Felice Crocetto and Luigi Napolitano
Published/Copyright: March 15, 2024

In the last decades several mobile health applications (MHAs) have been developed to assist healthcare and patients in different medical and surgical fields. Nowadays more than 325,000 m-health apps were available in major app stores with more than 3.7 billion downloads and this number continues to increase daily. MHAs collect health information, provide guidelines for maintaining a healthy lifestyle or information about disease, make medical diagnosis, and assist in disease prevention and management. Despite this, there are some drawbacks that could be addressed. First, lack of adherence to the guidelines: MHAs reported low adherence to EAU (European Association of Urology) guidelines. As previously showed [1], [2], [3], [4] MHAs were developed without healthcare support and the most important tool is their usability: they are easy to navigate, but the quality is low. Second, security and privacy remain an important debated issue yet. Suniave et al. [5] reported that MHAs developers often fail to provide app privacy policies: in fact, when reported, the privacy is not often focused on the app itself [6]. Smith et al. [7] reported that security of smartphone users is not high and sometimes many people have access to their phone. The quality rating studies conducted [8], [9], [10] show that transparency, privacy policies [11] and security documentation are still critical factors to take effort in. If on one hand MHA seem to lack of specific safeguards, on the other hand, as reported by Zhou et al. [12] there are some specific barriers and facilitators of users adopting MHA that can help developers to meet their needs [13]. EU General Data Protection Regulation is a cornerstone of privacy regulation but is not fully taken into account in all its predictions by app developers [14]. Inclusion of new health technologies is more than often something that simply “happens” and, usually the inclusion of artificial intelligence (AI) for supplementary or replacement purposes has serious social repercussions. Ethics stands as a safeguard of any indiscriminate introduction or total takeover in crucial sectors, such as Healthcare. Usually, the rush of technology is faster than the Law and not all new applications of artificial intelligence have gone through prior screening, as if apps did not require prior screening for marketing/use. According to EU Regulation 2017/745 [15], “‘medical device’ means any instrument, apparatus, appliance, software, implant, reagent, material or other article intended by the manufacturer to be used, alone or in combination, for human beings for one or more of the following specific medical purposes: – diagnosis, prevention, monitoring, prediction, prognosis, treatment or alleviation of disease”. Based on risk level and invasiveness, medical devices are divided into Class I, Class IIa, IIb and III. The conformity assessment procedure for class I devices should be carried out, as a rule, under the sole responsibility of manufacturers, in view of the low level of vulnerability associated with such devices. In addition to this existing regulation, in December 2023 the European Parliament reached a provisional agreement with the Council on the so-called “AI act”, the first law in the matter ever. The agreed text will now have to be formally adopted by both Parliament and Council to become EU law. The purpose of this Regulation is to promote a human-centric approach ensuring a high level of protection of health, safety, fundamental rights, and democracy while supporting innovation and improving. AI tools were introduced to support diagnostic practice and brought into direct contact with the patient. Thanks to the AI act, together with previous regulations adopted at the European level (both the one on personal data protection and medical devices) the protection of the right to privacy as well as patient safety has been safeguarded. However, several studies are necessary to assess the impact of these new technologies in clinical practice, especially from the point of view of patients’ perceptions, level of satisfaction, and any critical issue identified, just like repercussions on medical practice, possible liability profiles, and the changing physician-patient relationship that may find itself being filtered no longer by “Doctor Google” but by CE-marked medical devices.


Corresponding author: Enrico Sicignano, Department of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy, E-mail:

References

1. Napolitano, L, Fusco, GM, Cirillo, L, Abate, M, Mirone, C, Barone, B, et al.. Erectile dysfunction and mobile phone applications: quality, content and adherence to European Association guidelines on male sexual dysfunction. Arch Ital Urol Androl 2022;94:211–6. https://doi.org/10.4081/aiua.2022.2.211.Search in Google Scholar PubMed

2. Fusco, GM, Cirillo, L, Abate, M, Morra, S, Morgera, V, Barone, B, et al.. Male infertility, what mobile health applications “know”: quality analysis and adherence to European Association of Urology Guidelines. Arch Ital Urol Androl 2022;94:470–5. https://doi.org/10.4081/aiua.2022.4.470.Search in Google Scholar PubMed

3. Napolitano, L, Cirillo, L, Fusco, GM, Abate, M, Falcone, A, Morgera, V, et al.. Premature ejaculation in the era of mobile health application: a current analysis and evaluation of adherence to EAU guidelines. Arch Ital Urol Androl 2022;94:328–33. https://doi.org/10.4081/aiua.2022.3.328.Search in Google Scholar PubMed

4. Cirillo, L, Manfredi, C, Barone, B, Morgera, V, Cacace, G, Mastrangelo, F, et al.. Mobile health applications in kidney stone disease management: a reliable support for patients? Arch Ital Urol Androl 2023;95:11076. https://doi.org/10.4081/aiua.2023.11076.Search in Google Scholar PubMed

5. Sunyaev, A, Dehling, T, Taylor, PL, Mandl, KD. Availability and quality of mobile health app privacy policies. J Am Med Inf Assoc 2015;22:e28–33. https://doi.org/10.1136/amiajnl-2013-002605.Search in Google Scholar PubMed

6. Huckvale, K, Prieto, JT, Tilney, M, Benghozi, PJ, Car, J. Unaddressed privacy risks in accredited health and wellness apps: a cross-sectional systematic assessment. BMC Med 2015;13:214. https://doi.org/10.1186/s12916-015-0444-y.Search in Google Scholar PubMed PubMed Central

7. Smith, KA, Zhou, L, Watzlaf, VJ. User authentication in smartphones for telehealth. Int J Telerehabilitation 2017;9:3–12. https://doi.org/10.5195/ijt.2017.6226.Search in Google Scholar PubMed PubMed Central

8. Steubl, LS, Reimann, J, Simon, L, Terhorst, Y, Stach, M, Baumeister, H, et al.. A systematic quality rating of available mobile health apps for borderline personality disorder. Borderline Personal Disord Emot Dysregul 2022;9:17. https://doi.org/10.1186/s40479-022-00186-w.Search in Google Scholar PubMed PubMed Central

9. Benjumea, J, Ropero, J, Rivera-Romero, O, Dorronzoro-Zubiete, E, Carrasco, A. Privacy assessment in mobile health apps: scoping review. JMIR Mhealth Uhealth 2020;8:e18868. https://doi.org/10.2196/18868.Search in Google Scholar PubMed PubMed Central

10. Martínez-Pérez, B, de la Torre-Díez, I, López-Coronado, M. Privacy and security in mobile health apps: a review and recommendations. J Med Syst 2015;39:181. https://doi.org/10.1007/s10916-014-0181-3.Search in Google Scholar PubMed

11. Rosenfeld, L, Torous, J, Vahia, IV. Data security and privacy in apps for dementia: an analysis of existing privacy policies. Am J Geriatr Psychiatr 2017;25:873–7. https://doi.org/10.1016/j.jagp.2017.04.009.Search in Google Scholar PubMed

12. Zhou, L, Bao, J, Watzlaf, V, Parmanto, B. Barriers to and facilitators of the use of mobile health apps from a security perspective: mixed-methods study. JMIR Mhealth Uhealth 2019;7:e11223. https://doi.org/10.2196/11223.Search in Google Scholar PubMed PubMed Central

13. Rezaee, R, Khashayar, M, Saeedinezhad, S, Nasiri, M, Zare, S. Critical criteria and countermeasures for mobile health developers to ensure mobile health privacy and security: mixed methods study. JMIR Mhealth Uhealth 2023;11:e39055. https://doi.org/10.2196/39055.Search in Google Scholar PubMed PubMed Central

14. Alfawzan, N, Christen, M, Spitale, G, Biller-Andorno, N. Privacy, data sharing, and data security policies of women’s mHealth apps: scoping review and content analysis. JMIR Mhealth Uhealth 2022;10:e33735. https://doi.org/10.2196/33735.Search in Google Scholar PubMed PubMed Central

15. REGULATION (EU) 2017/745 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC: 01 July 2020.Search in Google Scholar

Published Online: 2024-03-15

© 2024 the author(s), published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 International License.

Articles in the same Issue

  1. Frontmatter
  2. Editorials
  3. Can small molecule GLP-1 agonists be the next first-line drugs in type-2 diabetes mellitus?
  4. From Dr. Google to CE-marked medical devices: need for ethical and legal safeguards
  5. Minireview
  6. Antioxidant therapy for hepatic diseases: a double-edged sword
  7. Reviews
  8. Effect of cannabinoids in mild-to-moderate cases of Crohn’s disease as compared to placebo: a systematic review and meta-analysis of randomised controlled trials
  9. Evidences and therapeutic advantages of donanemab in the treatment of early Alzheimer’s disease
  10. Alzheimer’s disease and clinical trials
  11. Original Articles
  12. Pioglitazone attenuate level of myeloperoxidases and nitic oxide in psoriatic lesion: a proof-of-concept study in a imiquimod induced psoriasis model in rat
  13. Protecting cardiomyocytes from hypoxia-reoxygenation injury, empaglifozin and liraglutide alone or in combination?
  14. Gasotransmitters do not prevent changes in transepithelial ion transport induced by hypoxia followed by reoxygenation
  15. High-intensity combination exercise has the highest effect on increasing serum irisin and interleukin 6 levels in women with obesity
  16. Impact of heat stress on thermal balance, hydration and cortical response among outdoor workers in hot environment – an exploratory report from North East India
  17. Maternal separation influences hepatic drug-metabolizing CYP450 gene expression without pathological changes in adult mice
  18. Case Report
  19. Preoperative CT diagnosis of perforated Meckel’s diverticulitis in a young patient: a case report
Downloaded on 12.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/jbcpp-2024-0020/html
Scroll to top button